Nisa Investment Advisors’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.59K | Hold |
1,331
| – | – | ﹤0.01% | 2670 |
|
|
2026
Q1 | $1.6K | Hold |
1,331
| – | – | ﹤0.01% | 2658 |
|
|
2025
Q4 | $1.31K | Hold |
1,331
| – | – | ﹤0.01% | 2672 |
|
|
2025
Q3 | $1.68K | Buy |
1,331
+344
| +35% | +$371 | ﹤0.01% | 2653 |
|
|
2025
Q2 | $1.1K | Sell |
987
-1,323
| -57% | -$1.54K | ﹤0.01% | 2717 |
|
|
2025
Q1 | $1.82K | Sell |
2,310
-14,825
| -87% | -$18.2K | ﹤0.01% | 2492 |
|
|
2024
Q4 | $28.3K | Sell |
17,135
-16
| -0.1% | -$40 | ﹤0.01% | 1832 |
|
|
2024
Q3 | $60K | Sell |
17,151
-351
| -2% | -$1.37K | ﹤0.01% | 1596 |
|
|
2024
Q2 | $57.4K | Buy |
17,502
+365
| +2% | +$1.6K | ﹤0.01% | 1625 |
|
|
2024
Q1 | $126K | Buy |
17,137
+297
| +2% | +$1.84K | ﹤0.01% | 1410 |
|
|
2023
Q4 | $63K | Buy |
16,840
+15,400
| +1,069% | +$36.4K | ﹤0.01% | 1573 |
|
|
2023
Q3 | $3.05K | Sell |
1,440
-109
| -7% | -$361 | ﹤0.01% | 2321 |
|
|
2023
Q2 | $7.37K | Sell |
1,549
-3,956
| -72% | -$21.8K | ﹤0.01% | 2298 |
|
|
2023
Q1 | $31K | Buy |
5,505
+5,205
| +1,735% | +$31.4K | ﹤0.01% | 1861 |
|
|
2022
Q4 | $3K | Sell |
300
-2,162
| -88% | -$40.6K | ﹤0.01% | 2336 |
|
|
2022
Q3 | $51K | Buy |
2,462
+362
| +17% | +$10.5K | ﹤0.01% | 1731 |
|
|
2022
Q2 | $52K | Sell |
2,100
-260
| -11% | -$7.17K | ﹤0.01% | 1717 |
|
|
2022
Q1 | $91K | Sell |
2,360
-180
| -7% | -$6.97K | ﹤0.01% | 1647 |
|
|
2021
Q4 | $105K | Sell |
2,540
-360
| -12% | -$20.4K | ﹤0.01% | 1499 |
|
|
2021
Q3 | $172K | Sell |
2,900
-200
| -6% | -$15.7K | ﹤0.01% | 1463 |
|
|
2021
Q2 | $269K | Sell |
3,100
-430
| -12% | -$34.6K | ﹤0.01% | 1315 |
|
|
2021
Q1 | $291K | Sell |
3,530
-400
| -10% | -$38.3K | ﹤0.01% | 1354 |
|
|
2020
Q4 | $357K | Buy |
3,930
+1,475
| +60% | +$91.6K | ﹤0.01% | 1267 |
|
|
2020
Q3 | $98K | Buy |
2,455
+1,900
| +342% | +$66.3K | ﹤0.01% | 1549 |
|
|
2020
Q2 | $19K | Buy |
555
+30
| +6% | +$894 | ﹤0.01% | 1784 |
|
|
2020
Q1 | $12K | Sell |
525
-75
| -13% | -$1.9K | ﹤0.01% | 1816 |
|
|
2019
Q4 | $12K | Hold |
600
| – | – | ﹤0.01% | 1798 |
|
|
2019
Q3 | $9K | Buy |
600
+170
| +40% | +$3.26K | ﹤0.01% | 1805 |
|
|
2019
Q2 | $9K | Hold |
430
| – | – | ﹤0.01% | 1776 |
|
|
2019
Q1 | $8K | Hold |
430
| – | – | ﹤0.01% | 1814 |
|
|
2018
Q4 | $6K | Hold |
430
| – | – | ﹤0.01% | 1766 |
|
|
2018
Q3 | $7K | Buy |
+430
| New | +$5.08K | ﹤0.01% | 1805 |
|
Other funds holding FATE
RG
JJ
Nisa Investment Advisors's FATE Position: Q2 2026 in Review
Nisa Investment Advisors held its Fate Therapeutics (FATE) position steady in Q2 2026 at 1,331 shares worth $3.59K. The position accounts for ﹤0.01% of the portfolio, ranked #2670.
Nisa Investment Advisors first reported a position in FATE in Q3 2018 and has held it in 32 quarters since. The position peaked at $357K in Q4 2020. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.
- Nisa Investment Advisors held 1,331 shares of Fate Therapeutics worth $3.59K as of Q2 2026.
- Nisa Investment Advisors left its Fate Therapeutics share count unchanged in Q2 2026.
- Fate Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #2670 holding.
- Nisa Investment Advisors first reported a position in Fate Therapeutics in Q3 2018 and has held it in 32 quarters since.
- Nisa Investment Advisors's Fate Therapeutics position peaked at $357K in Q4 2020.
- 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.
Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.